What is MAPS Public Benefit?
Founded in 1986, MAPS Public Benefit operates as a 501(c)(3) non-profit research and educational organization. The firm is dedicated to developing medical, legal, and cultural frameworks for the careful use of psychedelics and marijuana. Through its extensive research initiatives, the organization has become a primary authority in the field, focusing on clinical trials that explore the therapeutic potential of substances previously marginalized by mainstream medicine. Its market position is defined by its unique ability to synthesize academic research with advocacy, effectively influencing the global discourse on mental health treatments and substance regulation.
How much funding has MAPS Public Benefit raised?
MAPS Public Benefit has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in MAPS Public Benefit
PPP
Public-Private Partnership
What's next for MAPS Public Benefit?
With the infusion of this latest capital, MAPS Public Benefit is poised to accelerate its clinical development pipeline. The organization will likely prioritize the completion of multi-phase trials required for regulatory approval, while simultaneously expanding its educational outreach to ensure that the integration of these therapies into clinical practice is both safe and evidence-based. As the landscape for psychedelic medicine matures, the firm remains focused on scaling its research infrastructure to meet the growing demand for innovative mental health solutions, ensuring that its long-term strategic objectives align with evolving global health standards.
See full MAPS Public Benefit company page
